In phase 2 study of INO-5401 in combination with cemiplimab, Inovio Pharmaceuticals Inc (NASDAQ:INO) achieved success in ensuring the progression-free survival of patients who are diagnosed with GBM (glioblastoma multiforme). The phase 2 study is conducted using INO 9012, and INO 5401 in combination with a PD-1 blocking antibody – Libtayo on fifty-two patients diagnosed […]
Sign Up To Get Our Instant Alerts!
- Japanese Premier Declares COVID-19 State of Emergency in Tokyo 458 views
- JPMorgan Bringing Back Employees to Work From Office 451 views
- Ferari Poaches New CEO From Tech Industry 437 views
- China Unveils Maglev Train With a Top Speed of 600 kph 369 views
- Apple Employee Claims to Have Been Dismissed After Leading Movement Against Harassment 337 views